Search

Your search keyword '"Sandhu, Karamjeet S."' showing total 9 results
Start Over Author "Sandhu, Karamjeet S." Publication Year Range This year
9 results on '"Sandhu, Karamjeet S."'

1. Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.

Author

Jabbour, Elias, primary, Tholouli, Eleni, additional, Sandhu, Karamjeet S., additional, Shaughnessy, Paul, additional, Barba, Pere, additional, Guerreiro, Manuel, additional, Yallop, Deborah, additional, Logan, Aaron, additional, Abedi, Mehrdad, additional, Lao-Sirieix, Pierre, additional, Zhang, Yiyun, additional, Brugger, Wolfram, additional, Pule, Martin A., additional, Shah, Bijal D., additional, Bishop, Michael Russell, additional, Park, Jae H., additional, DeAngelo, Daniel J., additional, Peggs, Karl, additional, and Roddie, Claire, additional

Published
2024
Full Text
View/download PDF

2. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia.

Author

Othman, Tamer, Koller, Paul, Tsai, Ni‐Chun, Yang, Dongyun, Pourhassan, Hoda, Agrawal, Vaibhav, Ngo, Dat, Chen, Jason, Farol, Leonardo, Spielberger, Ricardo, Sahebi, Firoozeh, Al Malki, Monzr M., Cai, Ji‐Lian, Sandhu, Karamjeet S., Mansour, Joshua, Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Arslan, Shukaib, and Marcucci, Guido

Published
2024
Full Text
View/download PDF

4. Phase 1 Trial Investigating the Safety and Tolerability of Leflunomide in Patients with Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Author

Salhotra, Amandeep, primary, Yang, Dongyun, additional, Mokhtari, Sally, additional, Modi, Badri, additional, Al Malki, Monzr M., additional, Ali, Haris, additional, Amanam, Idoroenyi, additional, Karras, Nicole, additional, Sandhu, Karamjeet S., additional, Aribi, Ahmed, additional, Otoukesh, Salman, additional, Artz, Andrew S., additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Smith, Eileen, additional, Zeng, Defu, additional, Rosen, Steven, additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

5. Eculizumab Treatment Outcomes in Patients with Allogeneic Hematopoietic Cell Transplant (alloHCT)-Associated Thrombotic Microangiopathy (TA-TMA): A Retrospective Single-Center Experience

Author

Samara, Yazeed, primary, Yao, Janny, additional, Tsai, Ni-Chun, additional, Mokhtari, Sally, additional, Aldoss, Ibrahim, additional, Ali, Haris, additional, Sandhu, Karamjeet S., additional, Salhotra, Amandeep, additional, Stein, Anthony S., additional, Arslan, Shukaib, additional, Aribi, Ahmed, additional, Borogovac, Azra, additional, Malki, Monzr M. Al, additional, Blackmon, Amanda, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Artz, Andrew S., additional, Curtin, Peter, additional, Pourhassan, Hoda, additional, Koller, Paul, additional, Ball, Brian, additional, Agrawal, Vaibhav, additional, Spielberger, Ricardo, additional, Becker, Pamela S., additional, Stewart, F. Marc, additional, Smith, Eileen, additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Pullarkat, Vinod, additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

6. Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

Author

Salhotra, Amandeep, primary, Bejanyan, Nelli, additional, Yang, Dongyun, additional, Mokhtari, Sally, additional, Al Malki, Monzr M., additional, Sandhu, Karamjeet S., additional, Faramand, Rawan G, additional, Aldoss, Ibrahim, additional, Artz, Andrew S., additional, Aribi, Ahmed, additional, Elmariah, Hany, additional, Sahebi, Firoozeh, additional, Mansour, Joshua, additional, Ball, Brian, additional, Agrawal, Vaibhav, additional, Li, Ling, additional, Pullarkat, Vinod, additional, Forman, Stephen J., additional, Marcucci, Guido, additional, Stein, Anthony S., additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

7. ALL-502 Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden–Guided Dosing in the FELIX Phase 1b/2 Study

Author

Jabbour, Elias, Sandhu, Karamjeet S., Shaughnessy, Paul, Logan, Aaron C., Abedi, Mehrdad, Shah, Bijal D., Bishop, Michael R., Park, Jae H., DeAngelo, Daniel J., Raymond, Meera, Hu, Yanqing, Lao-Sirieix, Pierre, Saxena, Kapil, Brugger, Wolfram, Pule, Martin A., Shang, Justin, and Roddie, Claire

Published
2024
Full Text
View/download PDF

8. Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden–Guided Dosing in the FELIX Phase 1b/2 Study

Author

Jabbour, Elias, Sandhu, Karamjeet S., Shaughnessy, Paul, Logan, Aaron C., Abedi, Mehrdad, Shah, Bijal D., Bishop, Michael R., Park, Jae H., DeAngelo, Daniel J., Raymond, Meera, Hu, Yanqing, Lao-Sirieix, Pierre, Saxena, Kapil, Brugger, Wolfram, Pule, Martin A., Shang, Justin, and Roddie, Claire

Published
2024
Full Text
View/download PDF

9. Concurrent versus sequential or no triazole anti-fungal therapy in patients undergoing 7 + 3 plus midostaurin induction for FLT-3 acute myelogenous leukemia.

Author

Ngo, Dat, Tinajero, Jose, Zhang, Jianying, Stein, Anthony, Marcucci, Guido, Salhotra, Amandeep, Pullarkat, Vinod, Sandhu, Karamjeet S, Ball, Brian J, Pourhassan, Hoda, and Koller, Paul

Subjects
*ACUTE myeloid leukemia, *PROTEIN-tyrosine kinases, *MYCOSES, *ANTINEOPLASTIC agents, *CYTOCHROME P-450 CYP3A
Abstract

Midostaurin is a multikinase inhibitor approved for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 mutated (FLT3m) acute myeloid leukemia (AML). Azole antifungal medications are commonly used in AML and are known to interact with anti-cancer drugs such as midostaurin through the CYP3A pathway. However, there are no midostaurin related dose modifications recommended with strong CYP3A inhibitors.We retrospectively reviewed 40 patients between 2017–2022 and compared efficacy and safety outcomes in patients who received azole antifungals concurrently to those who did not receive an azole or received it sequentially to midostaurin for treatment of FLT3m AML.Median age of both groups was approximately 55 years and 70% of patients harbored FLT-3 internal tandem duplication mutations. Most patients in the concurrent arm were on either posaconazole (33%) or isavuconazole (50%) for antifungal prophylaxis and micafungin (72%) for the sequential/no azole arm. Overall CR/CRi rate with concurrent versus sequential/no azole were 72% and 77%, and non-hematologic grade 3 toxicities were 22% and 40% (p = 0.21), respectively. Rates of dose reductions (6% vs. 0%, p = 0.26) and held doses (17% vs. 14%, p = 0.79) were not different between concurrent and sequential/no azole. There were no differences in the rates of new fungal infection during induction between the two groups.Azoles given concurrently or sequentially with midostaurin were found to be equally safe and effective in the treatment of newly diagnosed FLT3 AML. Additional confirmatory studies are needed due to our limited sample size. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results